LY-364947 200 mg | 99.65%
TargetMol
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
More Information Supplier PageLY-364947
Search Results
LY-364947 100 mg | 99.65%
TargetMol
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
More Information Supplier PageLY-364947
Varespladib 25 mg | 100.00%
TargetMol
Varespladib, a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.
More Information Supplier PageVarespladib
Varespladib 2 mg | 100.00%
TargetMol
Varespladib, a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.
More Information Supplier PageVarespladib
LCL161 2 mg | 99.46%
TargetMol
LCL161, a SMAC mimetic, effectivity binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
More Information Supplier PageLCL161
Sepantronium bromide 100 mg | 99.82%
TargetMol
Sepantronium bromide (YM155) is a small-molecule proapoptotic agent with potential antineoplastic activity.
More Information Supplier PageSepantronium bromide
WP1066 5 mg | 99.07%
TargetMol
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
More Information Supplier PageWP1066
CNX-1351 25 mg | 98.83%
TargetMol
CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
More Information Supplier PageCNX-1351
Raltegravir 100 mg | 99.05%
TargetMol
Raltegravir is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
More Information Supplier PageRaltegravir
Raltegravir 2 mg | 99.05%
TargetMol
Raltegravir is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
More Information Supplier PageRaltegravir